- Conditions
- Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
- Interventions
- EIK1001, Pembrolizumab (KEYTRUDA®), Placebo, Paclitaxel + Carboplatin, Nab-paclitaxel + Carboplatin, Pemetrexed + Cisplatin /Carboplatin
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 18
- States / cities
- Daphne, Alabama • Glendale, California • Orange, California + 15 more
Recruitment Status
Recruiting clinical trials
Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
21991
Shown on this page
12
Current sort
Recently updated
Status scope
Recruiting
Additional filters apply within this recruitment status.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 1177–1188 of 21,991 matching trials with status Recruiting.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Multiple Myeloma
- Interventions
- JNJ-79635322, Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 35 more
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 96
- States / cities
- Little Rock, Arkansas • Duarte, California • La Jolla, California + 74 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- Tabirafusp tedromer, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 44
- States / cities
- Scottsdale, Arizona • Bakersfield, California • Glendale, California + 39 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Amivantamab, Cetuximab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin, Irinotecan Hydrochloride
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 81
- States / cities
- Gilbert, Arizona • Jonesboro, Arkansas • Springdale, Arkansas + 67 more
- Conditions
- Bilateral Arthritis of Wrist, Tendinopathy, Arthropathy, Compression Neuropathy, Bilateral Arthritis of Hands
- Interventions
- Digivibe Device
- Device
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 8 more
- Conditions
- Diffuse Large B Cell Lymphoma, Multiple Myeloma
- Interventions
- PointCheck
- Diagnostic Test
- Lead sponsor
- Leuko Labs, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 210 participants
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Honolulu, Hawaii • Louisville, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Obesity
- Interventions
- Asynchronous Remote Lifestyle Intervention, Synchronous Remote Lifestyle Intervention
- Behavioral
- Lead sponsor
- University of Connecticut
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Storrs, Connecticut
- Conditions
- Prostatic Neoplasms
- Interventions
- JNJ-78278343, JNJ-95298177, JNJ-87189401
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • New York, New York • Cleveland, Ohio + 1 more
- Conditions
- Prevention, Control
- Interventions
- Mindfulness Program, Active Comparator
- Behavioral
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Evanston, Illinois • Nashville, Tennessee
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 347
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 238 more